Company: TBPH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001104659-25-110382
Chunk: 2

Company: Theravance Biopharma, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
ITEM 1.    FINANCIAL STATEMENTS

​

THERAVANCE BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share data)

​​​​​​​​​September 30, ​December 31, ​    2025    2024Assets​​​​​​Current assets:​​​​​​Cash and cash equivalents ​$ 174,773​$ 37,797Short-term marketable securities​  154,907​  50,553Receivables from collaborative arrangements ​  18,267​  18,440Receivables from milestones and royalty assets​​ —​​ 50,000Other prepaid and current assets  ​​ 6,750​​ 4,277Total current assets ​  354,697​  161,067Long-term marketable securities​  3,029​  —Property and equipment, net ​  6,257​  7,418Operating lease assets​​ 25,450​​ 28,354Future contingent milestone and royalty assets​​ —​​ 144,200Restricted cash ​  836​  836Other assets​​ 25,191​​ 12,286Total assets ​$ 415,460​$ 354,161​​​​​​​Liabilities and Shareholders' Equity​​​​​​Current liabilities:​​​​​​Accounts payable ​$ 2,213​$ 2,242Accrued personnel-related expenses ​  10,330​  7,019Accrued clinical and development expenses ​  5,842​  1,058Accrued general and administrative expenses​​ 2,699​​ 2,987Operating lease liabilities​​ 10,914​​ 10,712Income tax payable​​ 4,074​​ 5,853Other accrued liabilities​  1,335​  2,214Total current liabilities ​  37,407​  32,085Long-term operating lease liabilities​​ 33,681​​ 39,108Future royalty payment contingency​​ 32,213​​ 30,334Unrecognized tax benefits​​ 79,165​​ 75,199Other long-term liabilities​​ 313​​ 1,890Commitments and contingencies (Note 11)​​​​​​​​​​​​​Shareholders’ Equity​​​​​​Preferred shares, $0.00001 par value per share: